Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview

Journal of Experimental and Clinical Cancer Research

Volumn 19, Issue 1, 2000, Pages 21-34

  Serrone, L ^a   Zeuli, M ^a   Sega, F M ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

DTIC based chemotherapy; Metastatic melanoma; Systemic chemotherapy

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; DACARBAZINE; LOMUSTINE; NITROSOUREA DERIVATIVE; TAMOXIFEN; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARMUSTINE; CISPLATIN; DACARBAZINE; HUMANS; MELANOMA; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0034124656     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Luce J.K., Thurman W.G., Isaacs B.L., Talley R.W.: Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388). Cancer Chemother. Rep. 54: 119-124, 1970.
2. Wagner D.E., Ramirez G., Weiss A.J. and Hill G. jr.: Combination phase I-II study of imidazole carboxamide (NSC 45388) Oncology 26:310-316, 1971.
3. Gottlieb J.A. and Serpick A.A.: Clinical evaluation of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules. Oncology 25: 225-233, 1971.
4. Cowan D.H. and Bergsagel D.E.: Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388). Cancer Chemother. Rep. 55: 175-181, 1971.
5. Pritchard K.I., Quirt I.C., Cowan D.H., Osoba D., Kutas G.J.: DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat. Rep. 64: 1123-1126, 1980.
6. Montgomery J.A.: Experimental studies at Southern Research Institutes with DTIC (NSC 45388). Cancer Treat. Rep. 60: 125-134, 1976.
7. Balch C.M., Reintgen D.S., Kirkwood J.M., Houghton A., Peters L., Kian Ang K.: Cutaneous Melanoma. In De Vita VT Jr, Hellman S, Rosemberg SA (eds): Cancer: Principles & Practice of Oncology. J.B. Lippincott, Philadelphia 1947-1994, 1997.
8. Lee S.M., Betticher D.C, Thatcher N.: Melanoma chemotherapy. Br. Med. Bull 51 (3): 609-630, 1995.
9. Marsh J.C.: Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Hepatol. 9: 790, 1989.
10. Bellet R.E., Mastrangelo M.J., Laucius J.F., Bodurtha A.J.: Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat. Rep. 60: 595-600, 1976.
11. Burke P.J., McCarthy W.H., Milton G.W.: Imidazole carboxamide therapy in advanced malignant melanoma. Cancer 27: 744-750, 1971.
12. Falkson C.I., Falkson G., Falkson H.C.: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J. Clin. Oncol. 9: 1403-1408, 1991.
13. Bajetta E., Di Leo A., Zampino M.G. et al.: Multicentre randomized trial of dacarbazinc alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J. Clin. Oncol. 12: 806-811, 1994.
14. Rozencweig M., von Hoff D.D., Slavik M., Muggia F.M.: Cisdiamminedichloroplatinum (II). A new anticancer drug. Ann. Intern. Med. 86: 803-812, 1977.
15. Ahmann D.L, Edmonson J.H., Frytak S., Kvols L.K., Bisel H.F., Rubin J.: Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum (II) and DTIC in patients with disseminated malienant melanoma. Cancer Treat. Rep. 62 (1): 151-153, 1978.
16. Goodnight J.E. Jr, Mosely H.S., Eilber F.R., Sarna G., Morton D.L.: cis-Dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer. Treat. Rep. 63: 2005-2007, 1979.
17. Oratz R., Speyer J.L., Green M., Blum R., Wernz J.C., Muggia F.M.: Treatment of metastatic malignant melanoma with dacarbazine and cisplatin. Cancer Treat. Rep. 71 (9): 877-878, 1987.
18. Fletcher W.S., Green S., Fletcher J.R., Dana B., Jewell W., Townsend R.A.: Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. Am. J. Clin. Oncol. 11 (5): 589-593, 1988.
19. Glover D., Glick J.H., Weiler C., Fox K., Guerry D.: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J. Clin. Oncol. 5 (4): 574-578, 1987.
20. Murren J.R., De Rosa W, Durivage H.J., Davis C., Makuch R., Portlock C.S.: High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 67: 1514-1517, 1991.
21. Steffens T.A., Bajorin D.F., Chapman P.B. et al.: A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer 68: 1230-1237, 1991.
22. Luger S.M., Kirkwood J.M., Ernstoff M.S., Vlock D.R.: High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J. Natl. Cancer Inst. 82: 1934-1937, 1990.
23. Atkins M.B.: The treatment of metastatic melanoma with chemotherapy and biologies. Curr. Opin. Oncol. 9: 205-213, 1997.
24. Costanza M.E., Nathanson L., Lenhard R. et al.: Therapy of malignant melanoma with an imidazole carboxamide and bischloroethyl nitrosourea. Cancer 30: 1457-1461, 1972.
25. Costanza M.E., Nathanson L., Schoenfeld D. et al.: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40: 1010-1015, 1977.
26. Schallreuter K.V., Wood J.M.: Fotemustine: a new nitrosourea drug in the treatment of melanoma. J. Cancer Res. Clin. Oncol. 116: 423, 1990.
27. Khayat D., Bizzari J.P., Frenay M. et al.: Interim report of phase II study of new nitrosourea S10036 in disseminated malignant melanoma. J. Natl. Cancer Inst. 80: 1407-1408, 1988.
28. Jacquillat C., Khayat D., Banzet P. et al.: Final report of phase II study of the nitrosourea fotemustine (S 10036) in 153 patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66 (9): 1873-1878, 1990.
29. Avril M.F., Bonneterre J., Delaunay M. et al.: Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother. Pharmacol. 27: 81-84, 1990.
30. Oliver V., Aliaga A., Lopez Lopez J.J. et al.: Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine. Eur. J. Cancer 29A (2): 287, 1993.
31. Merimsky O., Inbar M., Chaitchik S.: Fotemustine and DTIC combination in patients with disseminated malignant melanoma. Am. J. Clin. Oncol. 15(1): 84-86, 1992.
32. Gerard B., Aamdal S., Lee S.M. et al.: Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur. of Cancer 29A (5): 711-719, 1993.
33. Aamdal S., Gerard B., Bohman T., D'Incalci M.: Sequential administration of decarbazine and fotemustine in patients with disseminated malignant melanoma - an effective combination with unexpected toxicity. Eur. J. Cancer 28 (2/3): 447-450, 1992.
34. Binder M., Winkler A., Dorffner R., Glebowski E., Wolff K., Pehamberger H.: Fotomustine plus dacarbazine in advanced stage III malignant melanoma. Eur. J. Cancer 28 A(11): 1814-1816, 1992.
35. Moon J.: Combination chemotherapy in malignant melanoma. Cancer 26: 468-473, 1970.
36. Cohen S.M., Greenspan E.M., Weiner M.J., Kabakow B.:Triple combination chemotherapy of disseminated melanoma. Cancer 29: 1489-1495, 1972.
37. Carter R.D., Krementz E.T., Hill G.J. et al.: DTIC (NSC 45388) and combination therapy for melanoma I. Studies with DTIC, BCNU (NSC 409962), CCNU (NSC 79037), vincristine (NSC 67574), and hydroxyurea (NSC 32065). Cancer Treat. Rep. 60: 601-609, 1976.
38. Hill G.J., Krementz E.T., Hill H.Z.: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (Central Oncology Group Protocols 7130, 7131, and 7131A). Cancer 53: 1299-1305, 1984.
39. Costanzi J.J.: DTIC (NSC-45388) studies in the Southwest Oncology Group. Cancer Treat. Rep. 60: 189-192, 1976.
40. McKelvey E.M., Luce J.K., Vaitkevicius K. et al.: Bischloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer 39: 5-10, 1977.
41. Costanzi J.J., Vaitkevicius V.K., Quagliana J.M., Hoogstraten B., Coltman C.A. jr., Delaney F.C.: Combination chemotherapy for disseminated malignant melanoma. Cancer 35: 342, 1975.
42. Costanzi J.J., Al-Sarraf M., Groppe C. et al.: Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study. Med. Pediatr. Oncol. 10: 251-258, 1982.
43. De Wasch G., Bernheim J., Michel J., Lejeune F., Kenis V.: Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin in the treatment of stage III melanoma. Cancer Treat. Rep. 60: 1273-1276, 1976.
44. Seigler H.F., Lucas V.S. Jr., Pickett N.J., Huang A.T.: DTIC, CCNU, bleomycin and vicristine (BOLD) in metastatic melanoma. Cancer 46: 2346-2348, 1980.
45. Ahn S.S., Giuliano A., Kaiser L. et al.: The limited role of BOLD chemotherapy for disseminated malignant melanoma. Proceedings Am. Soc. Clin. Oncol. 2: 228 (Abstr), 1983.
46. Rumke P., Everall J.D., Mulder J.H., Rozencweig M., Czarnetzki B., Thomas D.: EORTC phase II trial of vindesine in advanced melanoma. Eur J. Cancer Clin. Oncol. 19: 1173-1174, 1983.
47. Young D.W., Lever R.S., English J.S.C., McKie R.M.: The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Cancer 55: 1879-1881, 1985.
48. York R.M., Foltz A.T.: Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 61: 2183-2186, 1988.
49. The Prudente Foundation Melanoma Study Group.: Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer 63: 1676-1680, 1989.
50. Pyrhönen S., Hahka-Kemppinen M. and Muhonen T.: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J. Clin. Oncol. 10: 1919-1926, 1992.
51. Punt C.J.A., van Herpen C.M.L., Jansen R.L.H., Vreugdenhil G., Muller E.W., De Mulder P.H.M.: Chemoimniunotherapy withe bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon a for metastatic melanoma: a multicentre phase II study. Br. J. Cancer 76 (2): 266-269, 1997.
52. Nathan F.E., Berd D., Sato T. et al.: BOLD + Interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J. Exp. Clin. Cancer Res. 16 (2): 201-208, 1997.
53. Carey R.W., Anderson J.R., Green M., Ellisson R.R., Nathanson L., Kennedy B.J.: Treatment of metastatic malignant melanoma with vinblastine, dacarbazine and cisplatin: a report from the Cancer and Leukemia Group B. Cancer Treat. Rep. 70 (3): 329-331, 1986.
54. Legha S.S., Ring S., Papadopoulos N, Plager C., Chawla S., Benjamin R.: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64: 2024-2029, 1989.
55. Buzaid A.C., Legha S.S., Winn R. et al.: Cisplatin (C), Vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial. Proceedings Am. Soc. Clin. Oncol. 12: 389 (Abstr), 1993.
56. Carmichael J., Atkinson R.J., Calman K.C., McKie R.M., Naysmith A.M., Smyth J.F.: A multicentre phase II trial of vindesine in malignant melanoma. Eur. J. Cancer Clin. Oncol. 18: 1293-1295, 1982.
57. Quagliana J.M., Stephens R.L., Baker L.H. et al.: Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group Study. J. Clin. Oncol. 2: 316-319, 1984.
58. Gundersen S.: Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat. Rep. 71 (11): 997-999, 1987.
59. Verschraegen C.F., Kleeberg U.R., Mulder J. et al.: Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the EORTC malignant melanoma cooperative group. Cancer 62: 1061-1065, 1988.
60. Jungnelius U., Ringborg V., Aamdal S. et al.: Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomized phase III trial. Eur. J. Cancer 34(9): 1368-1374, 1998.
61. Fisher R.I., Neifeld J.P., Lippman M.E.: Estrogen receptor in human malignant melanoma. Lancet 2: 337-338, 1976.
62. Nesbit R.A., Woods R.L., Tattersall M.H.N. et al.: Tamoxifen in malignant melanoma. N. Engl. J. Med. 301: 1241-1242, 1979.
63. Leichman C.G., Samson M.K., Baker L.H.: Phase II trial of tamoxifen in malignant melanoma. Cancer Treat. Rep. 66: 1447, 1982.
64. Creagan E.T., Ingle J.N., Green S.J., Ahman D.L., Jiang N.S.: Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat. Rep. 64: 199-201, 1980.
65. Del Prete S.A., Maurer L.H., O'Donnell J., Forcier R.J., Le Marbre P.: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 68: 1403-1405, 1984.
66. McClay E.F., Mastrangelo M.J., Bellet R.E. et al.: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat. Rep. 71 (5): 465-469, 1987.
67. McClay E.F., Mastrangelo M.J., Sprandio J.D. et al.: The importance of tamoxifen to a cisplatin containing regimen in the treatment of metastatic melanoma. Cancer 63: 1292-1295, 1989.
68. Richards J.M., Gilewski T.A., Ramming K., Mitchel B., Doane L.L., Vogelzang N.J.: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69: 427-429, 1992.
69. McClay E.F., Mastrangelo M.J., Berd D. et al.: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int. J. Cancer 50: 553-556, 1992.
70. Fierro M.T., Bertero M., Novelli M. et al.: Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res. 3: 127-131, 1993.
71. Reintgen D. and Saba H.: Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BC-NU, and tamoxifen. Semin. Surg. Oncol. 9: 251-255, 1993.
72. Lattanzi S.C., Tosteson T., Maurer L.H. et al.: Dacarbazine (D), cisplatin (C), and carmustine (B), +/-tamoxifen (T) in the treatment of patients (pts) with metastatic melanoma (MM): results of 5-year follow-up. Proceedings Am. Soc. Clin. Oncol. 12:390 (Abstr), 1993.
73. Lattanzi S.C., Tosteson T., Chertoff J. et al.: Dacarbazine, cisplatin, and carmustine, with or without tamoxifen for metastatic melanoma: 5-year follow-up. Melanoma Res. 5: 365-369, 1995.
74. Cocconi G., Bella M., Calabresi F. et al.: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New Engl. J. Med. 327 (8): 516-523, 1992.
75. Guerry D.I.V., Schucter L.M.: Disseminated melanoma: is there a new standard therapy. New Engl. J. Med. 327: 560-561, 1992.
76. Thomson D.B., Walpole E.T., Beadle G.F., Mc Leod G.R.S, Smithers B.M.: High dose tamoxifen does not enhance the activity of dacarbazine in metastatic melanoma: QMP 9105. Proceedings Am. Soc. Clin. Oncol. 12: 392 (Abstr), 1993.
77. McClay E.F. and McClay M.E.T.: Tamoxifen: is it useful in the treatment of patients with metastatic melanoma. J. Clin. Oncol. 12: 617-626, 1994.
78. Ferri W., Kirkwood J.M., Vlock D. et al.: Carboplatin and dacarbazine plus/minus tamoxifen for metastatic melanoma. Proceedings Am. Soc. Clin. Oncol. 12: 396 (Abstr), 1993.
79. Rusthoven J.J., Quirt I.C., Iscoe N.A. et al.: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J. Clin. Oncol. 14: 2083-2090, 1996.
80. Falkson C.I., Ibrahim J., Kirkwood J.M., Coates A.S., Atkins M.B., Blum R.H.: Phase III trial of dacarbazine versus dacarbazine with interferon alfa-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alfa-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 16: 1743-1751, 1998.
81. Saxman S.B., Meyers M.L., Chapman P.B. et al.: A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma. Proceedings Am. Soc. Clin. Oncol. 18: 536 (Abstr), 1999.
82. Stevens M.F.G., Hickman J.A., Langdon S.P. et al.: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazol (5,1-d)1,2,3,5-tetrazin-4 (3H)-one (CCRG 81045; M§B 39831) a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47: 5846-5852, 1987.
83. Bleehen N.M., Newlands E.S., Lee S.M. et al.: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13: 910-913, 1995.
84. Baker M., Zeman E., Hirst V., Brown J.: Metabolism of SR 4233 by chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 48: 5947-5952, 1988.
85. Bedikian A.Y., Legha S.S., Eton O. et al: Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann. Oncol. 8: 363-367, 1997.
86. Elsaid A.A., Menke D., Dorie M.J., Brown J.M.: Antimelanoma activity of tirapazamine in combination with dacarbazine (DTIC). Proceedings Am. Soc. Clin. Oncol. 16: 505 (Abstr), 1997.
87. Legha S.S., Ring S., Papadopoulos N., Raber M., Benjamin R.S.: A phase II trial of taxol in metastatic melanoma. Cancer 65: 2478-2481, 1990.
88. Feun L.G., Savaraj N., Schwartz M. et al.: Phase II trial of taxol and DTIC with filgrastim administration in advanced malignant melanoma (MM). Proceedings Am. Soc. Clin. Oncol. 16: 505 (Abstr), 1997.
89. Serrone L., Hersey P.: The chemoresistance of human malignant melanoma: an update. Melanoma Res. 9 (1): 51-58, 1999.
90. Xie K., Wang Y., Huang S. et al.: Nitric oxide-mediated apoptosis of k-1735 melanoma cells is associated with downregulation of bcl-2. Oncogene 15: 771-779, 1997.
91. Jansen B., Schlagbauer-Wadl H., Brown B.D. et al.: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4: 232-234, 1998.
92. Lakhani S., Selby P., Bliss J.M., Perren T.J., Gore M.E., M.c Elwain T.J.: Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br. J. Cancer 61: 330-334, 1990.
93. Ahmann D.L., Creagan E.T., Hahn R.G., Edmonson J.H., Bisel H.F., Schaid D.J.: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63: 224-227, 1989.
94. Luikart S.D., Kennealey G.T., Kirkwood J.M.: Randomized phase III trial of vinblastine, bleomycin and cis-dichlorodiammineplatinum versus dacarbazine in malignant melanoma. J. Clin. Oncol. 2: 164-168, 1984.
95. Berd D., Mastrangelo M.J.: Combination chemotherapy of metastatic melanoma. J. Clin. Oncol. 13 (3): 796, 1995.
96. Argawala S.S., Kirkwood J.M.: Interferons in melanoma. Curr. Opin. Oncol. 8: 167-174, 1996.
97. Sparano J.A., Dutcher J.P.: Interleukih-2 for the treatment of advanced melanoma. Hematol. Oncol. Ann. 1: 279-285, 1993.
98. Legha S.S., Gianan M.A., Plager C., Eton D.E., Papadopoulos N.E.J.: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 77: 89-96, 1996.
99. Marincola F.M., White D.E., Wise A.P., Rosenberg S.A.: Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol. 13: 1110-1122, 1995.
100. Keilholz U., Scheibenbogen C., Tilgen W. et al.: Interferon a and interleukin-2 in the treatment of malignant melanoma: a comparison of two phase II trials. Cancer 72: 607-614, 1993.
101. Richards J.M., Mehta N., Ramming K., Skosey P:. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 10: 1338-1343, 1992.
102. Khayat D., Borel C., Tourani J.M. et al.: Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma. J. Clin. Oncol. 12: 2173-2180, 1993.
103. Legha S.S., Ring S., Eton O. et al.: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interIeukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 16: 1752-1759, 1998.
104. Keilholz U., Stoter G., Punt C.J., Scheibenbogen C., Lejeune F., Eggermont A.M.: Recombinant interleukin-2 based treatment for advanced melanoma: the experience of the EORTC-Melanoma-Cooperative Group. Cancer J. Sci. Am. 3: S22-S28, 1997.
105. Keilholz U., Conradt C., Legha S.S. et al.: Results of interleukin-2 based treatment in advanced melanoma: a case record-based analysis of 631 patients. J. Clin. Oncol. 16: 2921-2929, 1998.